Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue

Vittorio Viti; Chiara Zanetta; Ruggero Capra; Andrea Municchi; Maria A. Rocca; Massimo Filippi

doi:10.1007/s00415-024-12553-4

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus

Massimo Filippi, Ruggero Capra, Diego Centonze, Claudio Gasperini, Francesco Patti, Paola Perini, Carlo Pozzilli, Maria A. Rocca, Antonio Uccelli, María Trojano

Article2021

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

Sara Guerrieri, Serena Marita Lazzarin, Chiara Zanetta, Agostino Nozzolillo, Massimo Filippi, Lucia Moiola

Article2024

10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)

Stephen L. Hauser, Ludwig Kappos, Massimo Filippi, Jerry S. Wolinsky, Martin S. Weber, Jacqueline Nicholas, Cathy Chognot, Hans‐Martin Schneble, Qīng Wáng, Gavin Giovannoni, Xavier Montalbán

Article2019

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

Chiara Zanetta, Micaela Robotti, Agostino Nozzolillo, Francesca Sangalli, Giuseppe Liberatore, Eduardo Nobile‐Orazio, Massimo Filippi, Lucia Moiola

Article2015

Self-esteem is associated with perceived stress in multiple sclerosis patients

Parthena Ifantopoulou, Artemios Artemiadis, Nikolaos Triantafyllou, George Chrousos, Ioannis Papanastasiou, Christina Darviri